Biotech Startup Junevity Raises $10M for Cell Reset Therapeutics Platform

Junevity, a biotechnology company aiming to prolong lifespan and healthspan by repairing cell damage from age-related diseases, has secured $10 million in seed funding led by Goldcrest Capital and Godfrey Capital. The company's RESET platform, based on research by co-founder Dr. Janine Sengstack at the University of California, San Francisco, uses human data and AI to identify genes regulating cell damage, and develops siRNA therapeutics against these targets.

The funding will be utilized to enhance the platform and develop therapeutic candidates in Type 2 diabetes, obesity, and frailty. Dr. Sengstack emphasized the potential of targeting transcription factors to rejuvenate aged human cells. The platform utilizes data from human diseases and AI to produce the Cell RESET Atlas, a compilation of promising transcription factor targets for therapeutic targeting.

Junevity's preclinical data shows promising results in Type 2 diabetes and obesity, demonstrating improved glucose control, insulin sensitivity, and significant weight loss with minimal side effects. The company plans to advance multiple clinical programs to combat aging-related diseases. Junevity's founding executive team includes experienced individuals driven by the mission to extend human longevity.

The company has also exclusively licensed relevant technology from UCSF and filed several patents for its siRNA therapeutic candidates. Junevity is committed to developing cell reset therapeutics for longevity, addressing diseases such as Type 2 diabetes, obesity, and frailty. The company's mission is to bring these therapeutics to the world for a longer and healthier lifespan.